National Institutes of Health: Skin Neoplasms trials

The registry lists 46 Skin Neoplasms studies with National Institutes of Health as lead sponsor. 2 are open to participants now and 27 have results posted.

Phase 1 12Phase 2 30Phase 3 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingNCT02621021Phase 2
• Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaRecruitingNCT00040352
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedNCT02129075Phase 2Results posted
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT02111863Phase 2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor CellsTerminatedNCT01495572Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT01468818Phase 2Results posted
• Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic MelanomaTerminatedNCT01369888Phase 1/2Results posted
• Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaTerminatedNCT01369875Phase 2Results posted
• Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...CompletedNCT01319565Phase 2Results posted
• Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01258855Phase 2Results posted
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompletedNCT01130519Phase 2Results posted
• Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...CompletedNCT01118091Phase 2Results posted
• MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00866177Phase 2Results posted
• Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat MelanomaCompletedNCT00665470Phase 2Results posted
• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced MelanomaTerminatedNCT00612222Phase 2Results posted
• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced MelanomaTerminatedNCT00610311Phase 2Results posted
• Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic LeukemiaCompletedNCT00563290Phase 2Results posted
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered LymphocytesTerminatedNCT00509496Phase 2Results posted
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered LymphocytesCompletedNCT00509288Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT00397982Phase 2Results posted
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00387751Phase 2Results posted
• Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin CancerCompletedNCT00126555Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3Results posted
• Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3Results posted
• M7824 Related Adverse Effects in Adults With CancerActive, not recruitingNCT04267861
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989559Phase 1
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Vitamin D Levels in the Skin of Healthy Subjects After Oral SupplementationCompletedNCT01447355Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• The Incidence of Breast and Other Cancers Among Female Flight AttendantsCompletedNCT00342407
• LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By SurgeryCompletedNCT00295958Phase 2
• T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney TransplantCompletedNCT00089180Phase 2
• Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedNCT00079131Phase 2
• S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
• Cancer Risk in Carriers of the Gene for Xeroderma PigmentosumCompletedNCT00046189
• Celecoxib in Preventing Skin CancerWithdrawnNCT00025051Phase 2
• Isotretinoin in Preventing Skin CancerCompletedNCT00025012Not applicable
• Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or TrichothiodystrophyCompletedNCT00001813